Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No slappie, not smart, just part of it. There is no reason for an 8% drop in sales price, except for manipulation.
slappie is paid to bash.
Techxen, it does seem that Italy is doing very well with Cytosorb. I am also excited about Aferetica's PerLife System that is being released. PerLife™ Is the First System Integrating a Sorbent Purification Technology to Perfuse, Cleanse, Recondition, and Preserve Harvested Solid Organs for Transplantation. PerLife™ is the first integrated system that incorporates sorbent purification to perfuse, cleanse, recondition, and preserve harvested kidneys and livers, which account for 89% of all solid organ transplants globally The PerSorb sorbent cartridge leverages CytoSorbents’ state-of-the-art adsorptive porous polymer technology, targeting the reduction of a broad range of toxins from the perfusate that can compromise organ function The PerLife™ system incorporates a unique fluid handling system, with specially designed disposables, cannulas, and proprietary perfusate solutions Active thermoregulation allows tight yet flexible control of temperatures (4-37oC) during perfusion Using an innovative design, the same equipment and disposables can be utilized to perfuse either kidneys or livers, simplifying the setup for customersThe goal of the PerLife™ system is to improve organ function and viability, while reducing the risk of primary graft failure and organ rejection. One major targeted use is the reconditioning of unusable or sub-optimally functioning “marginal” organs that are typically discarded. This may increase the availability of scarce, suitable organs and improve the clinical outcomes of complex and expensive transplantation procedures.
https://cytosorbents.com/aferetica-and-cytosorbents-debut-the-perlife-system-for-organ-preservation-and-rehabilitation-at-the-27th-international-congress-of-the-transplantation-society/
Disclosure: essay receives compensation from shorts. He owns no shares.
coldeterdivnvestor, so that you don't continue to post misinformation, I am providing a link to slide 12 from the Q22019 earning report that shows that 2 of the last 3 quarters were in fact record earnings for the company. They were not as you keep stating "3 lousy quarters".
https://cytosorbents.com/wp-content/uploads/2019/08/Q2-2019-Earnings-Presentation.pdf
What were the catalysts for it going down? None, other than the short attack.
Unfortunately, I believe that the shorts will keep the share price below $5 today, because it is option expiration day. Picking yesterday as the day for their main attack was not a coincidence.
wow, pearsby, you sunk to a new low. Blaming Dr. Chan for the short attack. That is low even by your standards. It is no coincidence that you reappeared this week and started up with your non truths. I hope that he sues you for slander.
Options expire today, their is no coincidence that the main thrust of the short attack is today. They started months ago, upped their attack after a good earnings report and posted their libelous article today. This involves some on this board also. It is also no coincidence that "pearsby" made his reappearance this week. They have been triggering stops and creating margin calls. I hope that they end up in jail.
There is nothing wrong with the company. You can see the desperation of the shorts as they have all come out and renewed pearsby as yet another alias. It appears that they have their sights on the options exporing on Friday.
colderterinvestor, the share price currently has no relationship to what management does, it is being heavily shorted. Probably by you.
burntoast, slappie can be right about the shares falling to $5 if he participated in the shorting, he knew it was coming.
well slappie you have exaggerated all of the negatives and ignored the positive accomplishments as you usually do. Yes losses are growing faster than revenues but management explained that issue. That they are hiring more direct sales to take over indirect sales areas. That should raise revenue by a lot, shortly. Dr. Chan did sell some shares, but you have seen that explained on this board, like I have, that it was he received more stock options, to cover taxes. He sold a very small amount of what he received. No, it is not two years behind the inflection point, we may be at the inflection point now with record sales this quarter, just won't know for sure until we look back later. What you aren't addressing is the 14% drop in sales price after very good earnings, which I am sure that you are cheering as a short.
fanthomphan, you are misrepresenting what I posted. I am saying that a very large number of the 400,000 shares sold after the earnings announcement were short shares. They triggered stop losses, because they know where they are at. The short members on IHUB and the yahoo board are just icing on the cake. They were relentless leading up to earnings and piled it on afterwards to keep the downward pressure. I personally can't recall many stocks getting hammered 14% in a day, unless they missed their earnings by a huge amount. We didn't miss on revenue at all, in fact had record earnings. Also, very good guidance. Now pearsby (Paul L.) has resurfaced with his nonsense as peachy. Coincidence? no. He has been here for many years and has never left, just changed his aliases. My guess is that he has around five at this time, normal for him.
The earnings for Q2 2019 were very good, with record revenue and with very good guidance. In a normal market, the share price would have increased. There is no way that it should have dropped 14%. The only reason was shorts, you could see it building here on IHUB and the yahoo board also as posters wrote of impending doom, of not meeting expectations, attacking Dr. Chan and other management, going to $3 etc. There is nothing wrong with the company, it is basically on track with their plans, revenue is increasing. I believe that without the shorts, we would easily be at $15, doubling within a year and doubling again in 2021. Eventually the shorts will be overwhelmed, just a matter of when. One poster wrote of Cases of the Week being stubbed toes, most of the cases that I have read, have saved lives or limbs of patients. As pearsby famously called them, Miracle Beads. Probably the only true thing he ever posted.
i see a Q3 2018 and Q1 2019 failure, but Q4 2019 was a record setter. How do you get three in a row?
stingman, do you have a link for us? Thank you.
I can read and comprehend. You can act as self righteous as you want but you attacked hemopure for pumping when he was clearly stating facts. You just proved my statement also, that you attack anyone that doesn't agree with your share price going to $5. My estimate is that we are headed upwards, with the upcoming record quarter and HemoDefend news.
Slappie believes that anyone not predicting $5 per share is pumping.
Dah, could you please post a link to the report? Thanks.
Perhaps CTSO is waiting for approval of the Cytosorb-XL before they make their big sepsis trials push?
Wow, Canes I am awed and impressed. Where do you see the share price in say two years, after REMOVE, REFRESH2 and HemoDefend approval? Hopefully, more of the pipeline products would also be in development by then.
Jacquescode, I agree with you. I am disappointed with the share price is as everyone here. However, I cannot see blaming Dr. Chan or conferences, over and over. Dr. Chan owns 526,281 shares. To insinuate that he isn't doing everything possible to increase share price is asinine. From $15, he has lost, on paper, over $4.2 million dollars. He attends conferences to try to increase shareholder value, all growing companies do this. He has brought this company very far in 8 years, perhaps without his leadership the share price would be even lower? I hope for it to head much higher soon, I expect it for sure when the next earnings and HemoDefend are announced.
slappie, I believe that you have CDS, Chan Derangement Syndrome. You are simply never going to agree with anything he does. I personally believe that we are fortunate to have him. While I hate the downward share price, I believe that it comes from an area that he cannot control. Several others have mentioned the movement around option time. I believe there is price manipulation, perhaps from the person/persons always posting negative posts, trying to influence sentiment.
why do you think the conference is useless? Most new companies utilize them.
In the 8k published on June 5, 2019, slide 16. The company estimates REFRESH 2 completion date as 2020 with potential FDA approval in 2021. They have been adding additional sites and will continue to do so, they know that the company value will at least double upon approval in the US. I believe the company over the negative posters that seem to be swarming like there is blood in the water. Also, Dr. Chan has given outlook for this quarter as the highest in company history.
The Universal Plasma is very exciting, with huge potential. It is largely funded by grant money. "“With the exception of the relatively uncommon type AB, or universal, plasma, most plasma contains blood-type-specific antibodies and must be cross-matched with the intended recipient ahead of time or risk serious transfusion reactions,” stated Phillip Chan, M.D., Ph.D., CEO at CytoSorbents. “By reducing these blood-type-specific antibodies, our goal is to create a cost-effective, reliable, and expanded source of universal plasma that can be administered immediately, without blood typing, in a wide range of emergent and nonemergent situations.”
https://www.genengnews.com/topics/bioprocessing/cytosorbents-wins-1m-to-develop-purification-platform-for-universal-blood-plasma/
wow, you would almost think that lakersrback, slappie and colderinvestor were all the same person.
slappie, I see down two days in a row, I don't see announcing a conference as causing it.
slappie, you are changing the subject, which was you stating that the announcement of Dr. Chan attending a conference made the share price drop.
slappie, you surely cannot truly believe that share price and the announcement of a conference are linked can you?
lakersrback, please stop your constant pumping of EDTXF on this board, it is getting old.
That doesn't make someone a crook, I would say good business sense. I would say someone trying to manipulate a stock by throwing inflammatory language and using multiple aliases would be a crook.
slappie, that has always been the case, the distributors must meet minimum purchase amount.
ssmmss, crooks? seriously, what kind of proof do you have?
sabai, this is not the first time that you have pushed your $5 call and it hasn't worked yet.
coldterdinvestor, I doubt that you hold any long shares at all and probably never have. I do believe that you short the company. Your posts are consistently negative, always. I myself drop companies that I don't like, that don't meet my expectations and that is normal. We all would like to have a better quarter but this is a growing company in a new exciting field and will have hiccups. Your constant whining gets old.
pearsby, please stop pumping EDTXF on post after post. It is getting tiresome.
Probably better than your buddy sabais projection of down to $5 or lower than he made 2 days ago.Also, I did call it my unicorn scenario, just to illustrate that the expansion soon to 100m shares did not necessarily mean dilution.
This is my Unicorn scenario that doesn't dilute. HemoDefend is quickly approved by the FDA and EU and sales are huge, also a year later after both REMOVE and REFRESH are approved sales are triples worldwide. Share price rises to $60 per share and the 32 million shares are split 3/1 to give everyone 3 shares worth $20 each for the one they hold now. No dilution.